GL
GLMD.US Galmed Pharmaceuticals Ltd
- Market cap
- USD 4.95M
- P/E
- -
- P/B
- 0.23x
- ROE
- -118.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GLMD.US undervalued?
Graham numberThe Graham number of Galmed Pharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Galmed Pharmaceuticals Ltd fundamental analysis
No fundamental analysis for Galmed Pharmaceuticals Ltd yet.
Galmed Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol t…
Full company profileGalmed Pharmaceuticals Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Galmed Pharmaceuticals Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 467K | 1.09M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 467K | 1.09M | 2.04M | -35.0K | -39.0K | -42.0K | -35.0K | -31.0K | -83.0K | - | - |
| Operating Income | -16.9M | -12.4M | -10.7M | -22.4M | -30.2M | -32.9M | -17.7M | -7.49M | -6.28M | -8.51M | -11.6M |
| EBITDA | -16.7M | -12.1M | -10.3M | -22.3M | -30.2M | -32.4M | -17.6M | -6.87M | -7.42M | -10.3M | -15.2M |
| Net Income | -17.0M | -12.3M | -9.86M | -20.5M | -28.8M | -32.5M | -17.9M | -6.91M | -7.52M | -10.3M | -15.1M |
| EPS | -179 | -118 | -65 | -116 | -162 | -158 | -85 | -240 | -65 | -19 | -16 |
| Balance Sheet | |||||||||||
| Total Assets | 16.5M | 19.6M | 90.6M | 77.1M | 52.4M | 36.6M | 16.6M | 16.6M | 18.5M | 18.6M | 18.3M |
| Total Liabilities | 5.38M | 3.85M | 2.71M | 7.29M | 8.23M | 6.11M | 3.14M | 2.75M | 2.17M | 2.85M | 5.55M |
| Shareholders' Equity | 11.1M | 15.8M | 87.9M | 69.9M | 44.2M | 30.5M | 13.4M | 13.9M | 16.3M | 15.8M | 12.7M |
| Cash & Short-term Investments | 15.4M | 19.0M | 90.2M | 75.5M | 50.9M | 34.8M | 13.8M | 12.6M | 15.3M | 18.2M | 11.4M |
| Total Debt | - | - | - | 352K | 216K | 229K | 215K | 41.0K | - | - | 129K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.1M | -12.1M | -9.02M | -14.9M | -26.3M | -32.9M | -18.5M | -6.14M | -5.88M | -6.32M | -8.14M |
| Capital Expenditure | 17.0K | 21.0K | 90.0K | 12.0K | 44.0K | 11.0K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -12.1M | -12.1M | -9.11M | -14.9M | -26.3M | -32.9M | -18.5M | -6.14M | -5.88M | -6.32M | -8.14M |
| Ratios | |||||||||||
| ROE | -153.1% | -77.9% | -11.2% | -29.3% | -65.2% | -106.5% | -133.1% | -49.8% | -46.0% | -65.3% | -118.4% |
| ROA | -103.1% | -62.6% | -10.9% | -26.5% | -54.9% | -88.7% | -107.9% | -41.6% | -40.6% | -55.3% | -82.5% |
| Net Profit Margin | -3,630.2% | -1,133.5% | -483.6% | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.01x | 0.00x | 0.01x | 0.02x | 0.00x | - | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Galmed Pharmaceuticals Ltd dividends
Galmed Pharmaceuticals Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Aug 19, 2026.
Who owns Galmed Pharmaceuticals Ltd
- Insiders 3.04%
- Institutions 1.89%
- Public & others 95.07%
- Shares outstanding 1.07M
- Free float 976K
Top funds holding GLMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nomura Healthcare Fund Class I | 1.70K | 0.02% | 0.00% | Jul 2026 |
Top institutions holding GLMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 86.9K | 1.04% | +663.06% | Jun 2026 |
| XTX Topco Ltd | 22.4K | 0.27% | +102.72% | Mar 2026 |
| Jane Street Group LLC | 16.4K | 0.20% | +35.52% | Mar 2026 |
| TWO SIGMA SECURITIES, LLC | 12.0K | 0.14% | -11.99% | Mar 2026 |
| UBS Group AG | 2.55K | 0.03% | +40.35% | Mar 2026 |
| BNP Paribas Arbitrage, SA | 600.00 | 0.01% | -33.33% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 157.00 | 0.00% | -47.32% | Mar 2026 |
| Wells Fargo & Co | 43.00 | 0.00% | +377.78% | Mar 2026 |
| TSFG, LLC | 17.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 16.00 | 0.00% | 0.00% | Mar 2026 |
| Federation des caisses Desjardins du Quebec | 14.00 | 0.00% | 0.00% | Mar 2026 |
| Advisor Group Holdings, Inc. | 5.00 | 0.00% | 0.00% | Mar 2026 |
| Hanson Mcclain Inc | 2.00 | 0.00% | 0.00% | Mar 2026 |
| ZRC WEALTH MANAGEMENT, LLC | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Dogwood Wealth Management LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
Galmed Pharmaceuticals Ltd company profile
- Company name
- Galmed Pharmaceuticals Ltd
- Ticker
- GLMD.US
- ISIN
- IL0011313900
- Exchange
- USA Stocks
- Listed since
- Mar 13, 2014
- Sector
- -
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- 16 Abba Hillel Road, Ramat Gan, Israel, 5250608
- Phone
- 972 3 693 8448
- Website
- eocn.com
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Galmed Pharmaceuticals Ltd management
6- Mr. Allen BaharaffCo-Founder, President, CEO & Chairman · born 1965
- Mr. Doron CohenChief Financial Officer · born 1967
- Mr. Guy NehemyaCOO & Data Protection Officer · born 1985
- Mr. Yohai Stenzler CPAChief Accounting Officer · born 1983
- Dr. Liat Hayardeny MBA, Ph.D.Chief Scientific Officer · born 1967
- Dr. Tali GorfineMedical Consultant · born 1970